The good news is that we have 3 vaccines to make to have good efficiency. This means that they protect people who receive the vaccine. Two of the vaccines are based on a new technology that has not been used before in vaccines. Athegh, technology is new, is not entirely unusual, since it is based on providing instructions (in the form of nucleic acid) so that its own cells create a protein that the virus does. Other existing vaccine technologies do the same, they only provide instructions in a different form of nucleic acid and supply in a different child or “package” (Figure 1).
Pfizer and Bionntech reported that their vaccine was 95% effective to prevent COVID-19 from 28 days after the first dose. They registered more than 43,000 people in the clinical trial and observed 170 cases of COVID-19. Of those 170 cases, only 8 were in the group that had recovered the vaccine. This is how they reached the effective value of 95%. There were 10 serious cases of COVID-19 and 9 or those were the placebo group. In addition, the vaccine was 94% effective in adults over 65. All this information comes from a press release, so the results have not yet been published and reviewed by pairs. The results are positive that companies have requested the authorization of emergency use of the FDA.
The limitations are that this vaccine requests 2 doses to achieve the informed efficacy and request storage and transport at an extremely low temperature, -70 ° C (-94 ° F) to maintain stability. This is good news but not the news of “saving the world”, due to storage and transportation requirements.
Modern also reported that his vaccine was 94% effective based on 95 cases of COVID-19 in the more than 30,000 participants in the clinical trial. Among the 95 cases, only 5 were in the group that received the vaccine. All cases of severe COVID-19 (11 cases) were in the placebo group. Like the results of the Pfizer and Bionntech vaccine, these results come from a press release. The European Medicines Agency is a review of this vaccine as part of the next step for the vaccination approach in Europe.
The limitations are that this vaccine requests 2 doses to achieve the informed efficacy and the vaccine requests a large amount of material that the Pfizer and Biontech vaccine. However, this vaccine is stable at -20 ° C (-4 ° F) for up to six months, under conditions refrigerated for up to 30 days and ambient temperature for up to 12 hours. This is closer to the news of “Save the World”.
These 2 vaccines use RNM, a type of instructions that cells use to produce proteins. Using the MRNA molecules, the cells injected with the vaccine make a protein of the Sars-COV-2 virus called Spike or S. Protein S is required for the virus to enter the cells. Therefore, an immune response mounted against protein S has a high probability of generating immunity that avoids infection. This hypothesis seems to be true in the results of clinical trials with HRNA -based vaccines.
Astrazeneca also reported positive results with his vaccine. Your vaccine also provides cell instructions to make SARS-COV-2 protein. However, the instructions are packaged inside a designed virus called adenovirus chimpanzee. This adenovirus cannot be replicated and, instead, it is used as a delivery system for the instructions to make S. the advantage of this type of vaccine is that it is a DNA vaccine that is administered inside a virus particle, which is more stable than a lipid lipid (Figure 1) (Figure 1).
Astrazeneca reported results from a study with 23,000 participants who were in one of the following groups: a group received 2 doses of an average dose followed by a complete dose, a second received 2 doses of the amount of complete dose, and the last and the last dose of dose instité instité instité instité instité instité instité instité instité instité instité instité instin. I urged the insert to insert. I registered. I registered. I registered. I will be registered. I will be registered. I will be registered. I will be inserted. The different dosing regimes had different effectiveness: the average dose followed by a complete dose had an efficacy of 90% and the complete dose followed by another complete dose had a 62% effectiveness. Therefore, many news reports have declared the average of 70%. Since the average dose/complete dose regime had a better effect and that less material would be requested, it seems unlikely that Astrazeneca process with the two complete dose regime. However, different groups, such as older people, can respond differently and benefit more from the highest dosing regime.
Among the things we still do not find if any of the vaccines of thesis 3 prevents asymptomatic disease or the spread of the virus. Nor do we know how much immunity will last. What we do know is that the vaccines that are in development seem to work and that with combinations of varosit vaccines, we will reach the news of “saving the world.”
Press releases
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-bemit-emergengency-use-authorization
https://www.pfizer.com/News/press-release/press-release-detail/pfizer-and-biontech- Conclude-fase-3-study-covid-19-vaccine
https://investors.modernatx.com/news-releases/news-release-details/moderns-covid-19-vaccine-candate-meets-primary-eficacy
https://investors.modernatx.com/news-releases/news-release-details/european-medicines-engly-begins-rolling-review-moderns-mrna
https://investors.modernatx.com/news-releases/news-release-details/moderna-nounces-longer-Shelf-life-its-covid-19-vaccine
Clinical trials
Study to describe the security, tolerability, immunogenicity and effectiveness of candidates for the RNA vaccine against COVID-19 in healthy individuals
A study for evaluative efficacy, safety and immunogenicity of the ARNM-1273 vaccine in adults over 18 to prevent COVID-19
Phase III study double blind, controlled with placebo AZD1222 For the prevention of COVID-19 in adults
Science articles
More people receive COVID-19 twice, suggestion immunity decreases rapidly in some
‘Just Beautiful’: Another Covid-19 vaccine, of the modern newcomer, succeeds in a large-scale trial
Cover image
CITE AS: NR GOUCH, Good News on the Covid-19 Front. Biossendipia (November 23, 2020) https://www.biosendipity.com/good-news-on-the-covid-19-front/.
]